2 February 2015 - French medical technology company Implanet (Paris: IMPL) (Euronext: IMPL) has been definitively granted intellectual protection for its Jazz technology in Europe until 2031 (under patent number EP 2521500), the company said on Monday.

Implnet specialises in vertebral and knee-surgery implants.

This patent applies to the entire Jazz system and definitively secures full protection of the implant's technical characteristics.

Founded in 2007 and based near Bordeaux, Implanet is a medical technology company that manufactures implants for orthopedic surgery. Its flagship product, the Jazz latest-generation implant, aims to treat spinal pathologies requiring vertebral fusion surge.

Protected by four families of international patents, Jazz has obtained 510(k) regulatory clearance from the Food and Drug Administration in the United States and the CE mark.